NorthView Acquisition Corp. Files Q1 2024 10-Q

TL;DR

NorthView Acquisition Corp. filed its Q1 2024 10-Q. All systems go.

AI Summary

NorthView Acquisition Corp. filed its 10-Q for the quarterly period ended March 31, 2024. The company, incorporated in Delaware, is involved in the Surgical & Medical Instruments & Apparatus industry. Its principal executive offices are located at 207 West 25th St, 9th Floor, New York, NY 10001.

Why It Matters

This filing provides investors with an update on NorthView Acquisition Corp.'s financial performance and operational status for the first quarter of 2024.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new information presented.

Key Players & Entities

• NorthView Acquisition Corp. (company) — Registrant
• March 31, 2024 (date) — Quarterly period end date
• 207 West 25th St, 9th Floor, New York, NY 10001 (location) — Principal executive offices address
• 001-41177 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NVAC The Nasdaq Sto
• $11.50 — of common stock at an exercise price of $11.50 per whole share NVACW The Nasdaq Stock
• $11.13 — k were redeemed at a per share price of $11.13. In January 2024, $1,565,078 was paid f
• $1,565,078 — share price of $11.13. In January 2024, $1,565,078 was paid from the Trust Account to rede

Filing Documents

• ea0207292-10q_northview.htm (10-Q) — 572KB
• ea020729201ex31-1_northview.htm (EX-31.1) — 11KB
• ea020729201ex31-2_northview.htm (EX-31.2) — 10KB
• ea020729201ex32-1_northview.htm (EX-32.1) — 4KB
• ea020729201ex32-2_northview.htm (EX-32.2) — 5KB
• 0001213900-24-086609.txt ( ) — 4529KB
• nvac-20240331.xsd (EX-101.SCH) — 47KB
• nvac-20240331_cal.xml (EX-101.CAL) — 22KB
• nvac-20240331_def.xml (EX-101.DEF) — 258KB
• nvac-20240331_lab.xml (EX-101.LAB) — 387KB
• nvac-20240331_pre.xml (EX-101.PRE) — 254KB
• ea0207292-10q_northview_htm.xml (XML) — 466KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. NORTHVIEW ACQUISITION CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2024 (Unaudited) December 31, 2023 Assets Current Assets: Cash $ 5,314 $ 4,519 Prepaid expenses and other current assets 60,750 6,750 Cash and marketable securities held in Trust Account — 1,565,078 Total Current Assets 66,064 1,576,347 Cash and marketable securities held in Trust Account 8,433,168 9,308,328 Total Assets $ 8,499,232 $ 10,884,675 Liabilities, Redeemable Common Stock and Stockholders' Deficit Current Liabilities: Accounts payable and accrued expenses $ 614,287 $ 449,114 Excise tax payable 1,874,990 1,864,106 Common stock to be redeemed (1) — 1,565,078 Income tax payable 84,176 49,061 Convertible promissory note 1,262,226 944,118 Due to related party 128,815 50,000 Total Current Liabilities 3,964,494 4,921,477 Deferred tax liability — 13,661 Warrant liabilities 661,362 156,639 Total Liabilities 4,625,856 5,091,777 Commitments and Contingencies (Note 6) Common stock subject to possible redemption, 738,075 and 833,469 shares at redemption value of approximately $ 11.34 and $ 11.10 at March 31, 2024 and December 31, 2023, respectively 8,369,579 9,252,208 Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 1,000,000 shares authorized; none issued and outstanding — — Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 5,193,750 shares issued and outstanding at March 31, 2024 and December 31, 2023 (excluding 738,075 and 833,469 shares subject to possible redemption at March 31, 2024 and December 31, 2023, respectively) 519 519 Accumulated deficit ( 4,496,722 ) ( 3,459,829 ) Total Stockholders' Deficit ( 4,496,203 ) ( 3,459,310 ) Total Liabilities, Redeemable Common Stock and Stockholders' Deficit $ 8,499,232 $ 10,884,675 (1) In connection with the special meeting of stockholders to vote on extending the Combination Period

View Full Filing

View this 10-Q filing on SEC EDGAR